An expert discusses alternative treatment options for a symptomatic patient with metastatic castration-resistant prostate ...

Patients with mCRPC prostate cancer have an elevated risk of fractures due to bone metastases and use of androgen receptor pathway inhibitors (ARPI).

An expert discusses the safety findings from the PEACE-3 study, highlighting the adverse events associated with the ...

Researchers said alpha particles are promising therapies that target cancer while minimizing the damage to nearby healthy tissues.

11:25 AM – 12:45 PM PST XOFIGO (radium-223 dichloride) Re-treatment of metastatic castration-resistant prostate cancer patients with radium-223 therapy in daily practice - Investigator-Initiated ...

The high risk of bone involvement in cases of hormone-refractory prostate cancer has previously been ... phase II trial of the alpha-emitter radium-223 (223 Ra) for the treatment of these patients.

to support the recovery and transportation of radium-226 to the USA, where the sources will be used as a feedstock to produce actinium-225, an alpha-emitting isotope which is increasingly used in ...